ATE452641T1 - Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate - Google Patents

Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate

Info

Publication number: ATE452641T1
Authority: AT; Austria
Prior art keywords: hydroxytestosterone; hydroxytestosterones; androsten; dihydroxy; derivatives
Prior art date: 2002-09-05

Application number

AT03794351T

Other languages

English (en)

Inventor

Evert Bunschoten

Bennink Herman Coelingh

Der Linden Rene Van

Original Assignee

Pantarhei Bioscience Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-05

Filing date

2003-09-05

Publication date

2010-01-15

2003-09-05 Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE452641T1 publication Critical patent/ATE452641T1/de

Links

KYGUQDTWUBBBSD-MJVYMRHDSA-N 15alpha-hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](C[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 KYGUQDTWUBBBSD-MJVYMRHDSA-N 0.000 title abstract 2
239000008203 oral pharmaceutical composition Substances 0.000 title 1
KYGUQDTWUBBBSD-YIJWYKPTSA-N (8r,9s,10r,13s,14s,17s)-15,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4O)O)[C@@H]4[C@@H]3CCC2=C1 KYGUQDTWUBBBSD-YIJWYKPTSA-N 0.000 abstract 3
YMCWOAZGWMZGQT-FPNLOETNSA-N 16alpha-hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YMCWOAZGWMZGQT-FPNLOETNSA-N 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000002243 precursor Substances 0.000 abstract 2
150000003515 testosterones Chemical class 0.000 abstract 2
YMCWOAZGWMZGQT-UHFFFAOYSA-N (16alpha,17beta)-16,17-Dihydroxyandrost-4-en-3-one Natural products O=C1CCC2(C)C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 YMCWOAZGWMZGQT-UHFFFAOYSA-N 0.000 abstract 1
KYGUQDTWUBBBSD-XJBBOAPUSA-N (8r,9s,10r,13s,14s,15r,17s)-15,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](C[C@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 KYGUQDTWUBBBSD-XJBBOAPUSA-N 0.000 abstract 1
YMCWOAZGWMZGQT-QFSSQGEMSA-N (8r,9s,10r,13s,14s,17r)-16,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](C(O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YMCWOAZGWMZGQT-QFSSQGEMSA-N 0.000 abstract 1
KYGUQDTWUBBBSD-UHFFFAOYSA-N 15alpha-hydroxymethyltestosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4O)O)C4C3CCC2=C1 KYGUQDTWUBBBSD-UHFFFAOYSA-N 0.000 abstract 1
YMCWOAZGWMZGQT-KYQPOWKGSA-N 16beta-hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H]([C@@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YMCWOAZGWMZGQT-KYQPOWKGSA-N 0.000 abstract 1
206010002261 Androgen deficiency Diseases 0.000 abstract 1
239000003098 androgen Substances 0.000 abstract 1
230000001548 androgenic effect Effects 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT03794351T 2002-09-05 2003-09-05 Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate ATE452641T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02078643		2002-09-05
PCT/NL2003/000621 WO2004022065A1 (en)	2002-09-05	2003-09-05	Pharmaceutical application of 15- or 16- substituted testosterone analogues

Publications (1)

Publication Number	Publication Date
ATE452641T1 true ATE452641T1 (de)	2010-01-15

Family

ID=31970390

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03794351T ATE452641T1 (de)	2002-09-05	2003-09-05	Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate

Country Status (9)

Country	Link
US (1)	US7943602B2 (de)
EP (1)	EP1551415B1 (de)
CN (2)	CN1694710B (de)
AT (1)	ATE452641T1 (de)
AU (1)	AU2003263663A1 (de)
CA (1)	CA2497838C (de)
DE (1)	DE60330695D1 (de)
ES (1)	ES2338782T3 (de)
WO (1)	WO2004022065A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2558393A1 (en)	2004-03-10	2005-09-22	Schering Aktiengesellschaft	Compositions comprising drospirenone molecularly dispersed
MY142989A (en)	2004-03-10	2011-02-14	Bayer Schering Pharma Ag	Stabilised supersaturated solids of lipophilic drugs
US7401307B2 (en) *	2004-11-03	2008-07-15	International Business Machines Corporation	Slack sensitivity to parameter variation based timing analysis
US9375437B2 (en) *	2010-06-18	2016-06-28	Lipocine Inc.	Progesterone containing oral dosage forms and kits
US8951996B2 (en)	2011-07-28	2015-02-10	Lipocine Inc.	17-hydroxyprogesterone ester-containing oral compositions and related methods
RS62297B1 (sr)	2011-11-23	2021-09-30	Therapeuticsmd Inc	Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
CA2898729C (en)	2012-11-14	2018-05-08	Abon Pharmaceuticals, Llc	Oral transmucosal drug delivery system
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru)	2014-05-22	2018-06-26	Терапьютиксмд, Инк.	Натуральные комбинированные гормонозаместительные составы и терапии
ES3005883T3 (en)	2015-06-22	2025-03-17	Lipocine Inc	17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
US9931349B2 (en)	2016-04-01	2018-04-03	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
CN119157100A (zh) *	2024-08-15	2024-12-20	北京星辉再生科技有限责任公司	用于模拟人类雄性激素型脱发的无创动物模型的构建方法及其模型和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB774064A (en) *	1954-08-17	1957-05-01	Upjohn Co	Steroids
US2793216A (en) *	1954-08-17	1957-05-21	Upjohn Co	15-oxy-androstenes and 15-oxy-19-norandrostenes
FR2035786A1 (en) *	1969-03-28	1970-12-24	Squibb & Sons Inc	A-d-glucosides of steroids contng 16a-and 17-oh gps
US6117446A (en) *	1999-01-26	2000-09-12	Place; Virgil A.	Drug dosage unit for buccal administration of steroidal active agents
AU5181200A (en)	1999-06-04	2000-12-28	General Hospital Corporation, The	Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
DE60045751D1 (de)	1999-09-30	2011-04-28	Harbor Biosciences Inc	Therapeutische Behandlung androgenrezeptorbedingter Leiden

2003
- 2003-09-05 CA CA2497838A patent/CA2497838C/en not_active Expired - Fee Related
- 2003-09-05 CN CN038248905A patent/CN1694710B/zh not_active Expired - Fee Related
- 2003-09-05 DE DE60330695T patent/DE60330695D1/de not_active Expired - Lifetime
- 2003-09-05 WO PCT/NL2003/000621 patent/WO2004022065A1/en not_active Ceased
- 2003-09-05 ES ES03794351T patent/ES2338782T3/es not_active Expired - Lifetime
- 2003-09-05 AT AT03794351T patent/ATE452641T1/de not_active IP Right Cessation
- 2003-09-05 US US10/526,730 patent/US7943602B2/en not_active Expired - Fee Related
- 2003-09-05 CN CN200910221753.4A patent/CN101785775B/zh not_active Expired - Fee Related
- 2003-09-05 AU AU2003263663A patent/AU2003263663A1/en not_active Abandoned
- 2003-09-05 EP EP03794351A patent/EP1551415B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US7943602B2 (en)	2011-05-17
CN1694710B (zh)	2012-09-05
CN101785775A (zh)	2010-07-28
DE60330695D1 (de)	2010-02-04
CN1694710A (zh)	2005-11-09
ES2338782T3 (es)	2010-05-12
AU2003263663A1 (en)	2004-03-29
US20060122158A1 (en)	2006-06-08
EP1551415B1 (de)	2009-12-23
EP1551415A1 (de)	2005-07-13
CA2497838A1 (en)	2004-03-18
WO2004022065A1 (en)	2004-03-18
CA2497838C (en)	2012-07-17
CN101785775B (zh)	2015-03-25

Legal Events

Date	Code	Title	Description
2010-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60330695D1 (de)	2010-02-04	Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
JP6740497B2 (ja)	2020-08-12	癌を治療するための方法及び組成物
US20080125401A1 (en)	2008-05-29	Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
YU54602A (sh)	2006-01-16	Drospirenon za terapiju zamene hormona
US20150290221A1 (en)	2015-10-15	Methods and compositions for treating cancer
CA2467222A1 (en)	2003-05-22	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
SE463074B (sv)	1990-10-08	Anvaendning av aromatashaemmare och antiandrogener foer framstaellning av laekemedel foer profylax och terapi av benign prostatahyperplasi
CA2467237A1 (en)	2003-05-22	Method of preventing or treating benign gynaecological disorders
NZ312303A (en)	2000-01-28	Novel nor-pregnanes for inducing hypothalamic effects
WO2001003687A3 (en)	2001-08-09	Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans
MY128482A (en)	2007-02-28	New hormonal composition and its use
NO955085D0 (no)	1995-12-14	Androstansteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
HUP9903747A2 (hu)	2001-05-28	Új eljárás mometazon-furoát előállítására
HUP0101005A2 (hu)	2001-08-28	Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
NO955084D0 (no)	1995-12-14	Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
RU2004116082A (ru)	2005-05-10	Применение (11бета, 17 бета)-11-(1,3-бензодиоксол-5-ил)-17-гидрокси-17-(1-пропинил) эстра-4,9-диен-3-она при лечении большого депрессивного расстройства
Nishino et al.	1989	Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1, 4-diene-3, 17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors
MX9700881A (es)	1997-04-30	Pregnanos y colanos como indicadores neuroquimicos del cambio en la funcion hipotalamica.
CA2421302A1 (en)	2003-03-03	4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
BR9816142A (pt)	2002-06-25	Esteróides de 19-nor-colano como iniciadores neuroquìmicos de mudança na função hipotalâmica humana
TH58099A (th)	2003-09-05	การใช้ และสารผสมแอนติโปรเจสตินในการรักษาโรคต่อมลูกหมาก
JO2334B1 (en)	2006-06-28	Drospirenone for hormone replacement therapy
KR20040073572A (ko)	2004-08-19	내인성 에스트로겐의 합성을 예방하는 약물의 투여와관련된 호소 증상의 치료에서의 티볼론